Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE

Anca D Askanase [1], Wei Tang,[2] Qing Zuraw,[3] Robert Gordon,[4] Betsy Brotherton,[4] Joan T Merrill[5]

For numbered affiliations see end of article.

Correspondence to
Dr Anca D Askanase; ada20@cumc.columbia.edu

ABSTRACT

Objective The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) system is a novel and simple SLE disease activity instrument, consisting of a tandem clinician-reported (ClinRO) and patient-reported (PRO) outcome measure. The aim of this study was to compare the LFA-REAL system with other SLE activity measures in the phase III trial of ustekinumab in patients with active SLE.

Methods This was a prespecified analysis of data from a randomised, double-blind, placebo-controlled, parallel-group trial conducted at 140 sites in 20 countries. Correlations were evaluated between the LFA-REAL ClinRO and PRO with a panel of clinician-reported and patient-reported disease activity measures commonly used in SLE clinical trials at baseline, week 24 and week 52. All p values are reported as nominal.

Results Trial participants included 516 patients with SLE with a mean (SD) age of 43.5 (8.9), of whom 482 (93.4%) were female. The LFA-REAL ClinRO correlated with Physician Global Assessment (r=0.39, 0.65 and 0.74, p<0.001), British Isles Lupus Assessment Group Index (r=0.43, 0.67 and 0.73, p<0.001) and SLE Disease Activity Index-2000 (r=0.35, 0.60 and 0.62, p<0.001). The LFA-REAL ClinRO arthralgia/arthritis score correlated well with active joint counts (r=0.54, 0.73 and 0.68, p<0.001) and the mucocutaneous global score correlated strongly with Cutaneous Lupus Erythematosus Disease Area and Severity Index total activity (r=0.57, 0.77 and 0.81, p<0.001). The LFA-REAL PRO demonstrated a moderate correlation with Functional Assessment of Chronic Illness Therapy-Fatigue (r=−0.60, −0.55 and −0.58, p<0.001), Lupus QoL physical health (r=−0.42, −0.47 and −0.46, p<0.001), SF-36v2 vitality (r=−0.40, −0.43 and −0.58, p<0.001) and SF-36v2 Physical Component Summary (r=−0.45, −0.53 and −0.53, p<0.001). The LFA-REAL ClinRO and PRO showed a moderate correlation with each other (r=0.32, 0.45 and 0.50, p<0.001).

Conclusions The LFA-REAL ClinRO and PRO showed varied levels of correlations (weak to strong) with existing physician-based lupus disease activity measures and patient-reported outcome instruments, respectively and were able to more accurately capture organ-specific mucocutaneous and musculoskeletal manifestations.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ SLE is a complex multisystem autoimmune disease and it remains challenging to accurately measure SLE disease activity in both clinical practice and research.

WHAT THIS STUDY ADDS

⇒ The study evaluated the correlations between the Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) clinician-reported (ClinRO) and patient-reported (PRO) with a panel of clinician-reported and patient-reported disease activity measures commonly used in SLE clinical trials in a prespecified analysis of data from the phase III trial of ustekinumab in patients with active SLE.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ The data from this study support further development of the LFA-REAL ClinRO and PRO as a flexible resource in the evaluation of lupus disease activity and its potential as a simple, user-friendly outcome measure for SLE studies.

More analyses are needed to determine areas in which patient-reported outcomes are most similar or different to physician-reported end points and the basis for differences.

INTRODUCTION

SLE is a complex multisystem autoimmune disease characterised by clinical heterogeneity and unpredictable flares that can affect virtually any organ.[1] Multiple clinical assessment tools have attempted to capture the heterogeneity and variability of SLE clinical pattern and disease course yet over 20 late phase therapeutic trials failed to produce interpretable results.[2] It remains challenging to accurately

measure SLE disease activity in both clinical practice and research.[3]

The SLE Disease Activity Index (SLEDAI), British Isles Lupus Assessment Group Index (BILAG) and Physician Global Assessment (PGA) are the most extensively used disease activity measures in large, international, multi-centre trials, and each has well-known limitations.[4–6] SLEDAI includes only 24 items which misses a number of possible manifestations, and does not include severity grading thus cannot capture variations in the severity of individual manifestations once a minimal threshold has been met for a defined manifestation.[7 8] BILAG-2004 includes a comprehensive list of 97 items categorised within 9 organ systems. Changes in severity are captured; however, glossary-based definitions lead to inaccurate quantification of change at the threshold between severity grades, and the consolidation of various features within one organ system into a single score impedes comparisons between patients with one or multiple active features within an organ.[9] The PGA is an overall summation of the clinical encounter that allows physicians to quantify both the degree of disease activity and also whether there has been clinically significant change from visit to visit. However, there is conflicting data on the interobserver reliability of PGA among lupus experts.[10 11] The PGA is widely used alone and in composite end points, including the SLE Responder Index 4 (SRI-4),[12] BILAG-Based Composite Lupus Assessment (BICLA),[13 14] remission[15] and Lupus Low Disease Activity (LLDAS) definitions.[16] However, moderate changes are difficult to distinguish or compare from patient to patient on a limited 100 mm scale, and since all manifestations are consolidated into one score major improvement in one organ cannot be distinguished from moderate improvement in multiple organs. All these instruments have been problematic to interpret in clinical trials and are often inconsistent with patient-reported outcomes.[17 18] There is no built-in methodology to explore the reasons for this inconsistency.

The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) system is a new SLE disease activity measure that consists of a tandem clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) that were developed using standard psychometric methodology and input from patients with lupus and clinicians.[19–21] LFA-REAL ClinRO includes nine organ domain Visual Analogue Scale (VAS) and subscales for individual symptoms to allow evaluation of patient progress at the level of individual manifestations, organs and total disease activity and to distinguish moderate change in all organs from major change in one organ. LFA-REAL PRO generates information on lupus disease activity that is parallel to the ClinRO assessments and could help to address reasons for discordance in differing opinions between physicians and patients.

The current study evaluated the construct validity of the LFA-REAL ClinRO and LFA-REAL PRO compared with established disease activity measures and PROs in the phase III, randomised, placebo-controlled study (LOTUS; ClinicalTrials.gov: NCT03517722) of usteki-numab in patients with active SLE.[22]

METHODS

Patient cohort

This is a prespecified analysis of data from a randomised, double-blind, placebo-controlled, parallel-group trial conducted at 140 sites in 20 countries.[22] Following the planned interim analysis, the sponsor discontinued the study due to lack of efficacy; accordingly, the number of patients included in the week 52 of current analysis is lower. Eligible patients were 18–75 years of age, fulfilled the Systemic Lupus International Collaborating Clinics (SLICC) 2012 SLE classification criteria[23] and had moderately to severely active SLE, as measured by a SLEDAI-2000 (SLEDAI-2K) score of ≥6 with at least 4 points for clinical (non-laboratory) manifestations. Additionally, either severe disease activity in one or more organs or moderate activity in two or more organs were required (BILAG-2004 organ scores of ≥1 A item or ≥2 B items). At screening, patients were required to be seropositive for ANAs, antidouble-stranded DNA antibodies or anti-Smith antibodies and to be receiving stable treatment with at least one of the following medications: prednisone or equivalent, an antimalarial agent or immunosuppressant agent (azathioprine, mycophenolate mofetil or methotrexate). Patients with active severe lupus nephritis or neuropsychiatric SLE were excluded. Disease activity was assessed using clinician-reported outcomes including SLEDAI-2K, BILAG, PGA, Clinician Global Impression of Change (CGIC), Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), swollen and tender joint counts, LFA-REAL ClinRO and SRI-4. BILAG Total Scores were calculated based on the numerical scoring proposed by Yee *et al*.[24] Patients completed several PROs including 36-item Short Form Health Survey (SF-36), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Patient Global Assessment, Patient Global Impression of Change (PGIC) and LFA-REAL PRO. The LFA-REAL PRO was only available in English at the study start, accordingly the data presented here were limited to the investigators and sites in the USA only.

LFA-REAL system

The LFA-REAL ClinRO includes eight domains: mucocutaneous, musculoskeletal, cardiorespiratory, neuropsychiatric, renal, haematological, constitutional and vasculitis; clinicians are asked to score only active lupus manifestations over the past month. In addition, for this trial, up to three 'other' domains could be assessed. Subscales are prespecified or can be added to record individual scores when there is more than one manifestation in each organ. For example, the mucocutaneous domain consists of one overall scale and three subscales (rash, alopecia and mucosal ulcers). The musculoskeletal includes one global scale and two subscales (arthralgia/arthritis and myalgia/myositis). This keeps the instrument quite

simple but allows flexibility for comprehensive scoring of all SLE manifestations. Each organ or individual item score is entered on a VAS from 0 to 100 mm, with anchors separating mild, moderate and severe disease, similar to the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) SLEDAI PGA.[5] The total score is the sum of each organ domain score including global scores of mucocutaneous and musculoskeletal domains.

The LFA-REAL PRO has seven domains: rash, symptoms of arthritis, muscle pain or aches, fatigue, fever, hair loss and body symptoms (which include chest pain, shortness of breath, swelling in legs and other); patients are asked to score only active lupus symptoms over the past month. It was developed as a measurement of disease activity from patient's perspective. The symptoms of arthritis domain were intentionally split into three subscales (joint pain, joint swelling and joint stiffness) and overall arthritis scale. After first scoring each of the arthritis subscales separately, the patient is asked to put them together and provide an overall arthritis score. This simple, stepwise process trains the patient to consider arthritis the same way that a clinician does. Furthermore, if the patient's report is inconsistent with that of the clinician, it can be determined which aspect of the arthritis is the basis for the discrepancy. For each manifestation, a VAS (0–100 mm) is used. The summary results which range from 0 to 700 with the overall arthritis scale are reported.

Further description of the LFA-REAL can be found elsewhere.[19–21]

Statistical analyses

Correlation coefficients and nominal p values were generated for correlations between the LFA-REAL ClinRO or LFA-REAL PRO and the other disease measures using the Spearman's rank-order or Pearson's correlations based on appropriateness. Analyses were performed to ascertain relationships between different disease severity measurements and not treatment efficacy. Therefore, pooled (combined) treatment groups were used. Corresponding domains of the LFA-REAL ClinRO and the LFA-REAL PRO were compared, as were correlations between the LFA-REAL ClinRO and PRO skin domains and the CLASI as well as the LFA-REAL arthritis measures versus the active (tender and swollen) joint counts. A p value (two-sided) <0.05 was considered clinically relevant in all analyses. Data are exploratory and were not adjusted for multiple comparisons. A receiver operating curve (ROC) was generated to evaluate the LFA-REAL ClinRO Score change from baseline in terms of other response measures (SRI-4, BICLA, SLEDAI-2K Improvement or BILAG Improvement). Area under the curve (AUC) estimates were based on a logistic regression model for response (yes) with the LFA-REAL ClinRO Score change from baseline as the single covariate; 95% CIs were estimated using the Wald method. As a post hoc summary, estimates of sensitivity and specificity for multiple cut-off points of LFA-REAL ClinRO Score change from baseline

at week 52 in terms of SRI-4 and BICLA response were generated at three selected points of clinical interest and three optimal cut-off points identified by commonly used methods (sensitivity/specificity equity, closest distance to ROC 'ideal point' and Youden index).

RESULTS

Five hundred sixteen patients were evaluated of whom 482 (93.4%) were female, the mean age was 43.5 years and mean disease duration 8.9 years. The demographic and clinical characteristics of the patients are included in online supplemental table 1 and were described in detail elsewhere.[22] The LFA-REAL ClinRO and PRO evaluations were performed at the baseline, week 24 and week 52 study visits. The LFA-REAL PRO was only available in English at the time of this study and as such was completed only in the USA by patients with good English proficiency.

The number of patients included in each correlation analysis shown in tables 1–4 are available in online supplemental table 2. The numbers of patients available for ClinRO analyses at baseline, week 24 and week 52 were 494, 426 and 241, respectively. The numbers of patients available for PRO analyses at baseline, week 24 and week 52 were 117, 116 and 77, respectively.

Correlations between the LFA-REAL ClinRO and other SLE disease activity measures

At baseline, the total LFA-REAL ClinRO Score correlated weakly with SLEDAI-2K and PGA (r=0.35 and 0.39, p<0.001), and moderately with BILAG (r=0.43, p<0.001). At weeks 24 and 52, the total LFA-REAL ClinRO Score strongly correlated to the SLEDAI-2K score (r=0.60 and 0.62, p<0.001), the BILAG score (r=0.67 and 0.73, p<0.001) and the PGA (r=0.65 and 0.74, p<0.001) (see table 1A).

Correlations between PGA and BILAG or SLEDAI-2K were very weak at baseline (r=0.17 and 0.09, p<0.001), and were moderate at week 24 (r=0.51 and 0.45, p<0.001) and week 52 (r=0.57 and 0.52, p<0.001) (table 1C). The estimated AUC for LFA-REAL ClinRO Score change from baseline to weeks 24 and 52 were 0.76 for SRI-4 (fair) and 0.70 for BICLA (fair) at both time points (online supplemental table 3). As a post hoc summary, LFA-REAL ClinRO change from baseline at week 52 cut-off points to discriminate SRI-4 and BICLA responders from nonresponders were assessed and are included in online supplemental table 3 and figure 4. Based on the closest distance to ROC 'ideal point', the sensitivity and specificity of LFA-REAL ClinRO were 75% and 68% at the cut-off point of −55 in discriminating SRI-4 response, and 76% and 57% at the cut-off point of −58 in discriminating BICLA response.

Correlations between the numerical change in the LFA-REAL ClinRO and SRI-4 response between baseline and weeks 24 and 52 were moderate (r=−0.38 and −0.40, p<0.001), and even less robust with BICLA (r=−0.31 and

Table 1 Correlations between LFA-REAL ClinRO and SLE disease activity measures, LFA-REAL PRO and other PRO measures, PGA with SLEDAI and BILAG at baseline, 24 and 52 weeks

A	LFA-REAL ClinRO			B	LFA-REAL PRO			C	PGA		
	Baseline	Week 24	Week 52		Baseline	Week 24	Week 52		Baseline	Week 24	Week 52
PGA	0.39	0.65	0.74	FACIT-F	−0.60	−0.55	−0.58	BILAG	0.17	0.51	0.57
BILAG	0.43	0.67	0.73	Lupus QoL	−0.42	−0.47	−0.46	SLEDAI-2K	0.09	0.45	0.52
SLEDAI-2K	0.35	0.60	0.62	SF-36v2 vitality	−0.40	−0.43	−0.58				
				SF-36 PCS	−0.45	−0.53	−0.53				

Correlation scale: very weak: 0–0.2; weak: 0.2–0.4; moderate: 0.4–0.6; strong: 0.6–0.8; very strong: 0.8–1.0. P<0.001 across all correlation analyses.
(A) Correlations between LFA-REAL ClinRO Total Score and SLE disease activity measures. LFA-REAL ClinRO; LFA-REAL PRO; SLEDAI-2K; BILAG; PGA.
(B) Correlations between LFA-REAL PRO Total Score and PRO measures. LFA-REAL PRO; SF-36; SF-36 PCS; Lupus QoL; FACIT-F. The LFA-REAL PRO increases with disease severity while the other PROs increase with improvement, accounting for the inverse correlations observed.
(C) Correlations between PGA and SLEDAI and BILAG.
BILAG, British Isles Lupus Assessment Group 2004 Index Total Score; ClinRO, clinician-reported outcome; FACIT-F, Functional Assessment of Chronic Illness Therapy Fatigue Scale; LFA-REAL, Lupus Foundation of America Rapid Evaluation of Activity in Lupus; Lupus QoL, Lupus Quality of Life questionnaire; PGA, Physician Global Assessment; PRO, patient-reported outcome; SF-36, 36-item Short-Form Health Survey; SF-36 PCS, 36-item SF-36 Physical Component Summary; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.

−0.33, p<0.001), and LLDAS (r=−0.11, p=0.064; r=−0.27, p=0.002) (table 2A and 2B).

Further analyses were performed to estimate AUC value (estimated AUC (95% CI)) for the LFA-REAL ClinRO Score change from baseline to weeks 24 and 52 and showed 0.76, 95% CI (0.71 to 0.80) and 0.76, 95% CI (0.70 to 0.83) in terms of SRI-4 response, and 0.70, 95% CI (0.65 to 0.75) and 0.70, 95% CI (0.64 to 0.77) BICLA response (online supplemental table 3); LFA-REAL ClinRO Score change from baseline to week 52 was 0.74, 95% CI (0.67 to 0.81) in terms of SLEDAI-2K (≥4)

Improvement and 0.68, 95% CI (0.62 to 0.75) in terms of BILAG Improvement.

Correlations between the LFA-REAL PRO and other PRO measures

A correlation was observed between LFA-REAL PRO and FACIT-F at baseline (r=−0.60, p<0.001), which slightly decreased at week 24 (r=−0.55, p<0.001) and week 52 (r=−0.58, p<0.001). Similar correlations were present at baseline, week 24 and week 52 between LFA-REAL PRO and Lupus QoL physical health (r=−0.42, −0.47 and

Table 2 Correlation between LFA REAL ClinRO Total Score from baseline and composite response measures/disease activity measures, and LFA-REAL PRO change form baseline with other PROs at 24 and 52 weeks

A	LFA-REAL ClinRO change from baseline		B	LFA-REAL PRO change from baseline	
	Week 24	Week 52		Week 24	Week 52
DORIS remission	−0.09	−0.20	FACIT-F	−0.32	−0.44
LLDAS	−0.11	−0.27	Lupus QoL	−0.22	−0.44
BICLA response	−0.31	−0.33	SF-36v2 vitality	−0.21	−0.49
SRI-4 response	−0.38	−0.40	SF-36 PCS	−0.32	−0.42
PGA	0.48	0.53			
BILAG	0.43	0.40			
SLEDAI-2K	0.51	0.51			

Correlation scale: very weak: 0–0.2; weak: 0.2–0.4; moderate: 0.4–0.6; strong: 0.6–0.8; very strong: 0.8–1.0.
(A) Correlations between the change in LFA-REAL ClinRO Total Score from baseline and composite response measures and change from baseline in other disease measures. P<0.001 across all correlation analyses except with DORIS remission at week 24 (p=0.064) and week 52 (p=0.002), and LLDAS at week 24 (p=0.029).
(B) Correlations between change in LFA-REAL PRO score from baseline with change in other PRO measures from baseline to weeks 24 and 52. P<0.001 across all correlation analyses except Lupus QoL at week 24 (p=0.024), and SF-36v2 vitality at week 24 (p=0.033). The LFA-REAL PRO increases with disease severity while the other PROs increase with improvement, accounting for the inverse correlations observed.
BICLA, BILAG-based Composite Lupus Assessment; BILAG, British Isles Lupus Assessment Group 2004 Index Total Score; ClinRO, clinician-reported outcomes; DORIS remission, clinical temission on treatment; FACIT-F, Functional Assessment of Chronic Illness Therapy Fatigue Scale; LFA-REAL, Lupus Foundation of America Rapid Evaluation of Activity in Lupus; LLDAS, Lupus Low Disease Activity State; Lupus QoL, Lupus Quality of Life questionnaire; PGA, Physician Global Assessment; PRO, patient-reported outcomes; SF-36, 36-item Short-Form Health Survey; SF-36 PCS, 36-item SF-36 Physical Component Summary; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; SRI-4, SLEDAI-2K SLE Responder Index.

Table 3 Correlations between LFA-REAL ClinRO and PRO scores, ClinRO rash and PRO rash, ClinRO alopecia and PRO hair loss, ClinRO arthralgia/arthritis and PRO overall arthritis at baseline, week 24 and week 52 visits as well as change from baseline to week 24 and week 52

	At visit			Change from baseline	
	Baseline	**Week 24**	**Week 52**	**Week 24**	**Week 52**
ClinRO arthralgia/arthritis and PRO overall arthritis	0.38	0.49	0.56	0.24	0.37
ClinRO alopecia and PRO hair loss	0.38	0.50	0.61	0.38	0.30
ClinRO rash and PRO rash	0.51	0.49	0.66	0.43	0.49
ClinRO total and PRO total	0.32	0.45	0.50	0.27	0.37

Correlation scale very weak: 0–0.2; weak: 0.2–0.4; moderate: 0.4–0.6; strong: 0.6–0.8; very strong: 0.8–1.0. P≤0.015 across all correlation analyses.
ClinRO, clinician-reported outcomes; LFA-REAL, Lupus Foundation of America Rapid Evaluation of Activity in Lupus; PRO, patient-reported outcomes.

−0.46, p<0.001), SF-36 PCS (r=−0.45, −0.53 and −0.53, p<0.001) and SF-36v2 vitality (r=−0.40, −0.43 and −0.58, p<0.001) (see table 1B). The LFA-REAL PRO increases with disease severity while the other PROs increase with

Table 4 Correlation between LFA REAL ClinRO PRO musculoskeletal and mucocutaneous components and individual components of disease activity measures

A	LFA-REAL ClinRO: arthralgia/arthritis				LFA-REAL PRO symptoms of arthritis: overall arthritis		
	Baseline	**Week 24**	**Week 52**		**Baseline**	**Week 24**	**Week 52**
SLEDAI arthritis	0.54	0.66	0.65		0.27	0.44	0.33
Subset: subjects with ≥8 active counts at baseline	0.30	0.72	0.79		0.29	0.59	0.51
Subset: subjects with ≥4 active counts at baseline	0.38	0.73	0.69		0.19	0.48	0.42
All subjects active joint count	0.54	0.73	0.68		0.22	0.51	0.42
B	**LFA-REAL ClinRO**				**LFA-REAL PRO**		
	Baseline	**Week 24**	**Week 52**		**Baseline**	**Week 24**	**Week 52**
ClinRO mucosal ulcers/SLEDAI mucosal ulcers	0.82	0.82	0.85		NA	NA	NA
ClinRO alopecia/SLEDAI alopecia	0.79	0.73	0.74	PRO hair loss/SLEDAI alopecia	0.36	0.35	0.48
ClinRO rash/SLEDAI rash	0.58	0.65	0.73	PRO rash/SLEDAI rash	0.25	0.31	0.60
ClinRO mucocutaneous global/BILAG mucocutaneous	0.48	0.66	0.76	PRO rash/BILAG mucocutaneous	0.22	0.30	0.53
ClinRO mucocutaneous global/CLASI total activity	0.57	0.77	0.81	PRO rash/CLASI erythema	0.42	0.42	0.61

Correlation scale very weak: 0–0.2; weak: 0.2–0.4; moderate: 0.4–0.6; strong: 0.6–0.8; very strong: 0.8–1.0. P≤0.05 across all correlation analyses.
(A) Correlations between LFA-REAL ClinRO arthralgia/arthritis and LFA-REAL PRO symptoms of arthritis, and their correlations with active joint counts, and SLEDAI arthritis. Active joint counts (62 joints) are defined as joints with pain and signs of inflammation. Tender (pain) joint count (64 joints) are defined as joints with pain on examination; LFA-REAL PRO symptoms of arthritis consist of three individual symptom domains each scored on 0–100 mm VAS. Overall arthritis is a 0–100 mm VAS indicating patient's global consideration of joint pain, swelling and stiffness.
(B) Correlations between LFA-REAL ClinRO mucocutaneous global and components with CLASI, BILAG and SLEDAI, LFA-REAL PRO rash and LFA-REAL PRO hair loss, with CLASI, BILAG and SLEDAI. CLASI is a measure of skin disease severity, with scores ranging from 0 (least severe) to 70 (most severe). LFA-REAL ClinRO mucocutaneous global is a 0–100 mm VAS as an overall consideration of three mucocutaneous domains: rash, alopecia, mucosal.
BILAG, British Isles Lupus Assessment Group Index; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; ClinRO, clinician-reported outcomes; LFA-REAL, Lupus Foundation of America Rapid Evaluation of Activity in Lupus; PRO, patient-reported outcomes; SLEDAI, SLE Disease Activity Index; VAS, Visual Analogue Scale.

improvement, accounting for the inverse correlations observed.

Correlations between the LFA-REAL ClinRO and PRO

The two components of the LFA-REAL system, ClinRO and PRO, correlated with each other weakly at baseline (r=0.32, p<0.001) but strengthened at week 24 and week 52 (r=0.45 and 0.50, p<0.001). The change from baseline of these two components correlated weakly at week 24 (r=0.27, p=0.005) and at week 52 (r=0.37, p=0.001) (see table 3).

Musculoskeletal and mucocutaneous subcomponents of the LFA-REAL

LFA-REAL ClinRO arthralgia/arthritis and LFA-REAL PRO overall arthritis joint involvements correlated moderately with each other (table 4A) at week 24 and week 52 (r=0.49 and 0.56, p<0.001). Each component of the patient-reported joint involvement was examined and showed similar degrees of correlation to the LFA-REAL ClinRO arthralgia/arthritis at week 24 and week 52, including joint pain (r=0.47 and 0.49, p<0.001), joint swelling (r=0.50 and 0.56, p<0.001) and joint stiffness (r=0.43 and 0.56, p<0.001). Strong correlations were observed between the LFA-REAL ClinRO and active joint counts (r=0.73 and 0.68, p<0.001), these correlations increased in strength in patients with higher active joint counts ≥4 (r=0.73 and 0.69, p<0.001) and ≥8 (r=0.72 and 0.79, p<0.001). On the other hand, joint involvement reported by patients (LFA-REAL PRO symptoms of arthritis) correlated only moderately with active joint counts (r=0.51 and 0.42, p<0.001) at week 24 and week 52. This correlation also gained strength in patients with active joint counts ≥8 (r=0.59 and 0.51, p<0.001). The evaluation of individual components of the LFA-REAL ClinRO and PRO (joint pain and joint swelling) did not change the strength of these correlations.

Mucocutaneous involvement (table 4B) scored by the clinicians (LFA-REAL ClinRO mucocutaneous global) correlated strongly with CLASI total activity score at week 24 (r=0.77, p<0.001) and week 52 (r=0.81, p<0.001). Hair loss reported by patients (LFA-REAL PRO hair loss) correlated moderately with physicians' assessment of alopecia (LFA-REAL ClinRO alopecia) at week 24 (r=0.50, p<0.001) and more strongly at week 52 (r=0.61, p<0.001). Additionally, rash scored on the LFA-REAL ClinRO and LFA-REAL PRO correlated moderately at baseline and week 24 (r=0.51 and 0.49, respectively, p<0.001), and strongly at week 52 (r=0.66, p<0.001). The evaluation of individual components of the LFA-REAL ClinRO (rash, mucosal ulcers and alopecia) and PRO (rash and hair loss) did not change the strength of these correlations.

DISCUSSION

The LFA-REAL system was developed to capture evaluations of the same manifestations by both clinicians and patients so that a more complete picture of lupus disease activity can be evaluated.[19–21] The data presented here describe the measurement properties of the LFA-REAL compared with both clinician-reported and patient-reported outcome measures in a phase III clinical trial of ustekinumab which involved patients with moderate-to-severe SLE. The trial did not meet its primary end point and was stopped based on the futility analysis but provided significant data for this analysis.

The data show that the LFA-REAL ClinRO correlated moderately or strongly with SLEDAI-2K, BILAG and PGA. Previous smaller studies reported similar correlations between LFA-REAL ClinRO and Hybrid SLEDAI or PGA.[19 21 25 26] In the current analysis, the LFA-REAL ClinRO showed a stronger correlation with PGA (r=0.39, 0.65 and 0.74, p<0.001) than SLEDAI-2K (r=0.35, 0.60 and 0.62, p<0.001). The LFA-REAL ClinRO Total Score correlated well with BILAG Total Index (r=0.43, 0.67 and 0.73, p<0.001) in this international trial, although lower than that reported from the preliminary test done in 2015 by the authors (r=0.933, p<0.001),[21] and a second study carried out in 2017 by lupus clinicians (r=0.81, p<0.001) and clinical investigators (r=0.88, p<0.001).[25] However, the change in LFA-REAL ClinRO from baseline at weeks 24 and 52 correlated weakly with BICLA (r=−0.31 and −0.33, p<0.001) and SRI-4 (r=−0.38 and −0.40, p<0.001).

The LFA-REAL correlates well with the PGA, since it is a summation of organ or symptom-specific PGA scales added together. The relatively weaker correlations of BILAG and SLEDAI-2K with PGA compared with the LFA-REAL at baseline, week 24 and week 52 suggest that the LFA-REAL has the potential to integrate various aspects of disease activity similar to the PGA.

The LFA-REAL PRO Total Score, as a disease activity PRO, correlated moderately with SF-36 PCS (r=−0.53, p<0.001), Lupus QoL physical health (r=−0.46, p<0.001), SF-36v2 vitality (r=−0.58, p<0.001) and FACIT-F (r=−0.58, p<0.001). These correlations from international patients were lower than those reported from an Italian cohort of 110 consecutive patients with SLE where the correlation between the LFA-REAL PRO and FACIT-F (r=−0.817, p<0.001) and SF-36 PCS (r=−0.753, p<0.001) were strong or very strong.[27] Taken together, the accumulating data do suggest a potential utility for the LFA-REAL PRO in reflecting fatigue and overall physical functioning.

Many of the correlations evaluated in this study grew stronger postbaseline visits, indicating a potential learning curve that brings both patients and clinicians into increasingly analogous frames of reference over time. The LFA-REAL ClinRO and PRO correlated moderately with each other at week 52, suggesting some progress in integrating the perspective of the clinician and patient when focus is purposefully directed to similar aspects of disease. This possibility is supported by the fact that none of the three components of arthritis that the patients were instructed to score to build their total arthritis score showed greater or less correlation to the clinicians' arthritis scoring than the others. Nevertheless, more work needs to be done to fully understand the reasons for the discordance between patient report and physician assessment of SLE disease

activity, a problem which has been demonstrated by multiple previous studies.[18 26 28–30]

One goal of developing the LFA-REAL is to provide a simple, user-friendly system that can provide an accurate global disease activity score while also providing reliable individual organ scores. The LFA-REAL clinicians' arthralgia/arthritis scores correlated with active joint counts moderately (r=0.54, p<0.001) at baseline and strongly at week 24 and week 52 (r=0.73 and 0.68, p<0.001); the mucocutaneous score correlated moderately, strongly and very strongly with CLASI total activity (r=0.57, 0.77 and 0.81, p<0.001) at baseline, week 24 and week 52, respectively. The strong correlations with arthritis and rash support the potential of LFA-REAL as an end point measurement in clinical trials.[7–9]

Strengths of the LFA-REAL include the simplicity and speed of its use and the minimal requirement for specialised training to accurately score the instrument. This was confirmed in a past study in which the scoring of clinicians untrained on outcome measures was compared with the scoring of expert trialists.[23] Weaknesses of the current study include the fact that the instrument was designed to be scored monthly but was only applied in the current trial three times, with each scoring date many months apart. Despite our efforts to simplify the LFA-REAL, there appears to be a learning curve in its use over time, so it might be interesting to try this application in a study using a washout or run-in period so that both patients and clinicians could gain experience before the time when randomisation to an intervention occurs. Another problem with intermittent scoring is that the gold standard of PGIC and CGIG could not be used, since they involve a recall involving change of disease activity from 1 month to the next. The optimal cut-off points to identify improvement in LFA-REAL ClinRO derived from these data will be further evaluated against CGIC improvement.

In sum, these data support the further development of the LFA-REAL ClinRO and PRO as a flexible resource in the evaluation of lupus disease activity and its potential as a simple, user-friendly outcome measure for SLE studies.

Author affiliations
¹Division of Rheumatology, Columbia University Irving Medical Center, New York City, New York, USA
²Department of Medicine, Westchester Medical Center, Valhalla, New York, USA
³Clinical Development Immunology, Janssen Research and Development LLC, Spring House, Pennsylvania, USA
⁴Data Science, IQVIA Inc, Durham, North Carolina, USA
⁵Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval The trial was performed in accordance with the principles of the Declaration of Helsinki and International Conference on Harmonisation guidelines for Good Clinical Practice and the results are reported elsewhere.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iD
Anca D Askanase http://orcid.org/0000-0003-4597-5023

REFERENCES

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. *N Engl J Med* 2008;358:929–39.
2. Askanase AD, Merrill JT. Measuring disease activity in SLE is an ongoing struggle. *Nat Rev Rheumatol* 2019;15:194–5.
3. Dall'Era M, Bruce IN, Gordon C, *et al*. Current challenges in the development of new treatments for lupus. *Ann Rheum Dis* 2019;78:729–35.
4. Buyon JP, Petri MA, Kim MY, *et al*. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. *Ann Intern Med* 2005;142(12 Pt 1):953–62.
5. Petri M, Kim MY, Kalunian KC, *et al*. Combined oral contraceptives in women with systemic lupus erythematosus. *N Engl J Med* 2005;353:2550–8.
6. Isenberg DA, Rahman A, Allen E, *et al*. BILAG 2004. development and initial validation of an updated version of the British Isles lupus assessment group's disease activity index for patients with systemic lupus erythematosus. *Rheumatology (Oxford)* 2005;44:902–6.
7. Jesus D, Rodrigues M, Matos A, *et al*. Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients. *Lupus* 2019;28:607–12.
8. Yee C-S, Farewell VT, Isenberg DA, *et al*. The use of systemic lupus erythematosus disease activity index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. *Rheumatology (Oxford)* 2011;50:982–8.
9. Thanou A, Merrill JT. Top 10 things to know about lupus activity measures. *Curr Rheumatol Rep* 2013;15:334.
10. Aranow C, Askanase A, Oon S, *et al*. Laboratory investigation results influence physician's global assessment (PGA) of disease activity in SLE. *Ann Rheum Dis* 2020;79:787–92.
11. Chessa E, Piga M, Floris A, *et al*. Use of physician global assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. *Rheumatology (Oxford)* 2020;59:3622–32.
12. Furie RA, Petri MA, Wallace DJ, *et al*. Novel evidence-based systemic lupus erythematosus Responder index. *Arthritis Rheum* 2009;61:1143–51.
13. Wallace DJ, Kalunian K, Petri MA, *et al*. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. *Ann Rheum Dis* 2014;73:183–90.

14 Wallace DJ, Strand V, Furie R, *et al*. Evaluation of treatment success in systemic lupus erythematosus clinical trials: development of the british isles lupus assessment group-based composite lupus assessment endpoint. *Arthritis Rheumatol* 2011;63:S885–6.

15 van Vollenhoven R, Voskuyl A, Bertsias G, *et al*. A framework for remission in SLE: consensus findings from a large international Task force on definitions of remission in SLE (DORIS). *Ann Rheum Dis* 2017;76:554–61.

16 Franklyn K, Lau CS, Navarra SV, *et al*. Definition and initial validation of a lupus low disease activity state (LLDAS). *Ann Rheum Dis* 2016;75:1615–21.

17 Leong KP, Chong EYY, Kong KO, *et al*. Discordant assessment of lupus activity between patients and their physicians: the Singapore experience. *Lupus* 2010;19:100–6.

18 Elera-Fitzcarrald C, Vega K, Gamboa-Cárdenas RV, *et al*. Discrepant perception of lupus disease activity: a comparison between patients' and physicians' disease activity scores. *J Clin Rheumatol* 2020;26(7S Suppl 2):S165–9.

19 Thanou A, James JA, Arriens C, *et al*. Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures. *Lupus Sci Med* 2019;6:e000365.

20 Askanase AD, Daly RP, Okado M. Development and content validity of the lupus foundation of america rapid evaluation of activity in lupus (LFA-realdevelopment and content validity of the lupus foundation of america rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity. *Health Qual Life Outcomes* 2019;17:99.

21 Askanase A, Li X, Pong A, *et al*. Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments. *Lupus Sci Med* 2015;2:e000075.

22 van Vollenhoven RF, Kalunian KC, Dörner T, *et al*. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. *Ann Rheum Dis* 2022;81:1556–63.

23 Petri M, Orbai A-M, Alarcón GS, *et al*. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum* 2012;64:2677–86.

24 Yee C-S, Cresswell L, Farewell V, *et al*. Numerical scoring for the BILAG-2004 index. *Rheumatology (Oxford)* 2010;49:1665–9.

25 Askanase AD, Nguyen SC, Costenbader K, *et al*. Comparison of the lupus Foundation of america-rapid evaluation of activity in lupus to more complex disease activity instruments as evaluated by clinical Investigators or real-world clinicians. *Arthritis Care Res (Hoboken)* 2018;70:1058–63.

26 Ugarte-Gil MF, Gamboa-Cardenas RV, Reátegui-Sokolova C, *et al*. Evaluation of the LFA-REAL clinician-reported outcome (clinro) and patient-reported outcome (pro): data from the Peruvian almenara lupus cohort. *Lupus Sci Med* 2020;7:e000419.

27 Elefante E, Tani C, Signorini V, *et al*. Evaluation of the lupus foundation of america-rapid evaluation of activity in lupus as a measure of systemic lupus erythematosus (SLE) disease activity from the clinician and the patient perspective: experience from an italian cohort. *Arthritis Rheumatol* 2020;72 Suppl 10:1–4231.

28 Alarcón GS, McGwin G Jr, Brooks K, *et al*. Systemic lupus erythematosus in three ethnic groups. XI. sources of discrepancy in perception of disease activity: a comparison of physician and patient visual analog scale scores. *Arthritis Rheum* 2002;47:408–13.

29 Neville C, Clarke AE, Joseph L, *et al*. Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. *J Rheumatol* 2000;27:675–9.

30 Askanase AD, Castrejón I, Pincus T. Quantitative data for care of patients with systemic lupus erythematosus in usual clinical settings: a patient multidimensional health assessment questionnaire and physician estimate of noninflammatory symptoms. *J Rheumatol* 2011;38:1309–16.

Supplemental Table 1. Summary of Key Baseline Demographic and Disease Characteristics

All Randomized Subjects	N=516
Female, %	93.4
Age, mean ± SD	43.5 ± 8.9
Race, %	
White	66.7
African American	8.1
Asian	20.0
Disease duration, mean ± SD	8.9 ± 7.8
SLEDAI-2K (0-105), mean ± SD	10.4 ± 3.5
PGA (VAS 0-3), mean ± SD	1.8 ± 0.4
BILAG, %	
>=1A	43.2
>=2B	57.0
Tender Joint Count, mean ± SD	14.6 ± 11.0
Swollen Joint Count, mean ± SD	8.8 ± 6.6
Joints with Both Tenderness & Inflammation, mean ± SD	8.3 ± 6.3
CLASI activity score (0-70), mean ± SD	8.2 ± 6.6
Anti-dsDNA Antibodies Positive (>75 kIU/L), %	36.8
Low Complement Present, %	
C3	42.4
C4	26.4
Patients with lupus nephritis, %	19.4
Concomitant Medications, % (mean ± SD dose, mg/day)	
Oral glucocorticoids, % (mean ± SD dose, mg/day)	79.8 (9.7 ± 5.1)
Antimalarials, %	73.3

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Lupus Sci Med

Supplemental Table 2a. Number of patients included in the correlations between LFA-REAL ClinRO and SLE disease activity measures, LFA-REAL PRO and other PRO measures, PGA with SLEDAI and BILAG at baseline, 24 and 52 weeks

	LFA-REAL ClinRO				**LFA-REAL PRO at visit**				**PGA**		
	Baseline	*Week 24*	*Week 52*		*Baseline*	*Week 24*	*Week 52*		*Baseline*	*Week 24*	*Week 52*
PGA	494	449	248	FACIT-F	114	117	77	BILAG	498	440	244
BILAG	480	443	248	Lupus QoL	114	117	77	SLEDAI 2K	512	425	237
SLEDAI-2K	494	449	248	SF-36 v2 Vitality	114	117	77				
				SF-36 PCS	114	117	77				

LFA-REAL ClinRO, Lupus Foundation of America Rapid Evaluation of Activity in Lupus Clinician Reported Outcome; LFA-REAL PRO, Lupus Foundation of America Rapid Evaluation of Activity in Lupus Patient Reported Outcome; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; BILAG, British Isles Lupus Assessment Group 2004 Index Total Score; PGA, Physician Global Assessment. LFA-REAL PRO, Lupus Foundation of America Rapid Evaluation of Activity in Lupus Patient Reported Outcome; SF-36, Short-Form Health Survey; SF-36 PCS, SF-36 Physical Component Summary; Lupus QoL, Lupus Quality of Life questionnaire; FACIT-F, Functional Assessment of Chronic Illness Therapy Fatigue Scale. SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; BILAG Index Total, British Isles Lupus Assessment Group 2004 Index Total Score; PGA, Physician Global Assessment.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Lupus Sci Med

Supplemental Table 2b. Number of patients included in the correlations between LFA REAL ClinRO Total Score from baseline and composite response measures/disease activity measures, and LFA-REAL PRO change from baseline with other PROs at 24 and 52 weeks

	LFA-REAL ClinRO Change from Baseline			LFA-REAL PRO change from baseline	
	Week 24	*Week 52*		*Week 24*	*Week 52*
DORIS Remission	441	242	FACIT-F	106	70
LLDAS	416	231	Lupus QoL	106	70
BICLA Response	435	239	SF-36v2 Vitality	106	70
SRI-4 Response	417	232	SF36-PCS	106	70
PGA	442	242			
BILAG	436	241			
SLEDAI-2K	419	234			

LFA-REAL ClinRO, Lupus Foundation of America Rapid Evaluation of Activity in Lupus Clinician Reported Outcomes; LFA-REAL PRO, Lupus Foundation of America Rapid Evaluation of Activity in Lupus Patient Reported Outcomes; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; BILAG, British Isles Lupus Assessment Group 2004 Index Total Score; PGA, Physician Global Assessment; SRI-4, SLEDAI-2K SLE Responder Index; BICLA, BILAG-based Composite Lupus Assessment; LLDAS, Lupus Low Disease Activity State; DORIS Remission, Clinical Remission on Treatment; SF-36, Short-Form Health Survey; SF-36 PCS, SF-36 Physician Component Summary; Lupus QoL, Lupus Quality of Life questionnaire; FACIT-F, Functional Assessment of Chronic Illness Therapy Fatigue Scale.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Lupus Sci Med

Supplemental Table 2c. Number of patients included in correlations between LFA-REAL ClinRO and PRO Scores, ClinRO Rash and PRO Rash, ClinRO alopecia and PRO Hair Loss, ClinRO Arthralgia/Arthritis and PRO Overall Arthritis at Baseline, Week 24 and Week 52 visits as well as Change from Baseline to Week 24 and Week 52.

	At Visit			Change from baseline	
	Baseline	*Week 24*	*Week 52*	*Week 24*	*Week 52*
ClinRO arthralgia/arthritis/ PRO overall Arthritis	114	116	77	105	70
ClinRO Alopecia and PRO Hair Loss	114	116	77	105	70
ClinRO Rash and PRO Rash	114	116	77	105	70
ClinRO Total and PRO Total	114	116	77	105	70

LFA-REAL ClinRO, Lupus Foundation of America Rapid Evaluation of Activity in Lupus Clinician Reported Outcomes; LFA-REAL PRO, Lupus Foundation of America Rapid Evaluation of Activity in Lupus Patient Reported Outcomes

Supplemental Table 2d. Number of patients included in correlation between LFA REAL ClinRO PRO Musculoskeletal and Mucocutaneous Components and individual components of disease activity measures

	LFA-REAL ClinRO: Arthralgia/arthritis				LFA-REAL PRO symptoms of arthritis: Overall Arthritis		
	Baseline	*Week 24*	*Week 52*		*Baseline*	*Week 24*	*Week 52*
SLEDAI Arthritis	494	452	252		114	116	77
Subset: Subjects with >= 8 Active Counts At Baseline	220	202	118		71	70	48
Subset: Subjects with >= 4 Active Counts At Baseline	413	380	216		102	102	67
All Subjects Active Joint Count	494	451	248		114	116	76

	LFA-REAL ClinRO				LFA-REAL PRO		
	Baseline	*Week 24*	*Week 52*		*Baseline*	*Week 24*	*Week 52*
ClinRO Mucosal Ulcers/SLEDAI Mucosal Ulcers	494	454	252		NA	NA	NA
ClinRO Alopecia/SLEDAI Alopecia	494	454	252	PRO Hair Loss/SLEDAI Alopecia	114	117	77
ClinRO Rash/SLEDAI Rash	494	454	252	PRO Rash/ SLEDAI Rash	114	117	77
ClinRO Mucocutaneous Global/BILAG Mucocutaneous	494	454	252	PRO Rash/BILAG mucocutaneous	114	117	77
ClinRO Mucocutaneous Global/CLASI Total Activity	489	452	250	PRO Rash/ CLASI Total activity	114	117	77

LFA-REAL ClinRO, Lupus Foundation of America Rapid Evaluation of Activity in Lupus Clinician Reported Outcomes; LFA-REAL PRO, Lupus Foundation of America Rapid Evaluation of Activity in Lupus Patient Reported Outcomes; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index is a measure of skin-disease severity, with scores ranging from 0 (least severe) to 70 (most severe).

Active Joint Counts (62 joints) are defined as joints with pain and signs of inflammation. Tender (Pain) Joint count (64 Joints) are defined as joints with pain on examination.

Lupus Foundation of America Rapid Evaluation of Activity in Lupus Patient Reported Outcomes (LFA-REAL PRO) Symptoms of Arthritis consist of 3 individual symptom domains each scored on 0-100 mm Visual Analogue Scale (VAS). Overall Arthritis is a 0-100 mm VAS indicating patient's global consideration of Joint pain, Swelling and Stiffness.

LFA-REAL ClinRO Mucocutaneous Global is a 0-100 mm VAS as an overall consideration of 3 Mucocutaneous domains: Rash, Alopecia, Mucosal.

Supplemental Table 3a. Summary of Area Under the Curve (AUC) for LFA-REAL ClinRO Score Change from Baseline In Discrimination of Disease Measure Responses: SRI-4, Composite SRI-4, BICLA; Presenting N and AUC (95% CI) For Pooled (Combined) Treatments

AUC (95% CI) for LFA-REAL ClinRO Score in Discrimination of:	Change from Baseline	
	Week 24	**Week 52**
SRI-4 Response	N=417 0.76 (0.71, 0.80)	N=232 0.76 (0.70, 0.83)
Composite SRI-4 Response	-	N=245 0.72 (0.66, 0.79)
BICLA Response	N=435 0.70 (0.65, 0.75)	N=239 0.70 (0.64, 0.77)

Area under the curve (AUC) is in terms of LFA-REAL ClinRO Score change from baseline in discrimination of the noted Response (SRI-4, Composite SRI-4, or BICLA). Estimates are based on a logistic regression model for Response (Yes) with LFA-REAL ClinRO Score change from baseline as the single covariate. 95% confidence intervals are in terms of the Wald method.

Supplemental Table 3b. Sensitivity and Specificity of LFA-REAL ClinRO Score Change from Baseline at Week 52 In Discrimination of SRI-4 Response; Presenting Six Cut-Points

| Cut-Point Selection Method: Either "Of Clinical Interest" or Through Use of Optimal Cut-Point Estimation	Cut-Point	Sensitivity	Specificity
Of Clinical Interest	-60	0.69	0.70
Sensitivity, Specificity Equality	-59	0.69	0.70
Closest Distance to ROC "Ideal Point"	-55	0.75	0.68
Of Clinical Interest	-50	0.79	0.61
Youden Index	-41	0.86	0.58
Of Clinical Interest	-40	0.88	0.54

The six cut-points within this table are selected as follows. Three cut-points are of general clinical interest: -60, -50, -40. In addition, 3 standard methods are used to estimate an optimal cut-point and, for these data, include: -59, -55, and -41. The 3 methods are described throughout literature and not expanded here.

Supplemental Table 3c. Sensitivity and Specificity of LFA-REAL ClinRO Score Change from Baseline at Week 52 In Discrimination of BICLA Response; Presenting Six Cut-Points

Cut-Point Selection Method: Either "Of Clinical Interest" or Through Use of Optimal Cut-Point Estimation	Cut-Point	Sensitivity	Specificity
Of Clinical Interest	-68	0.64	0.64
Sensitivity, Specificity Equality	-60	0.69	0.57
Closest Distance to ROC "Ideal Point"	-58	0.76	0.57
Of Clinical Interest	-50	0.83	0.49
Youden Index	-43	0.90	0.44
Of Clinical Interest	-40	0.90	0.39

The six cut-points within this table are selected as follows. Three cut-points are of general clinical interest: -60, -50, -40. In addition, 3 standard methods are used to estimate an optimal cut-point and, for these data, include: -59, -55, and -41. The 3 methods are described throughout literature and not expanded here.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Lupus Sci Med

Supplemental Figure 4a. Area Under the Curve (AUC) for LFA-REAL ClinRO Score Change from Baseline at Week 52 In Discrimination of SRI-4

Supplemental Figure 4b. Area Under the Curve (AUC) for LFA-REAL ClinRO Score Change from Baseline at Week 52 In Discrimination of BICLA